Tools / Trials and research FKBP1A: Peptidyl-prolyl cis-trans isomerase FKBP1A A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand.
Drugs that act on it : 7 Approved : 5 In phases 1 to 3 : 2 Sponsors : 5 Who Is On It, and How Far Along Every drug ChEMBL records acting on FKBP1A, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved5 Sirolimus Sirolimus SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials409 Tacrolimus anhydrous Tacrolimus anhydrous SponsorEledon Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials254 Temsirolimus Temsirolimus SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials164 Everolimus Everolimus SponsorNovartis Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials159 Pimecrolimus Pimecrolimus SponsorBausch Health ModalitySmall molecule ActionInhibitor Open trials4 Phase 31 Zotarolimus Zotarolimus SponsorCeric Sàrl ModalitySmall molecule ActionInhibitor Open trials9 Phase 11 Olocrolimus Olocrolimus SponsorNot known ModalityOther ActionInhibitor Open trials0
Modalities Modalities Share Copy link Download image (PNG)Drugs on this target by ChEMBL molecule type.
Small molecule 6 86%Small molecule Count6 Share86% Other 1 14%Other Count1 Share14%
The Landscape Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: FK506-binding protein 1A inhibitor.
Open Trials The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 37 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer Everolimus, Sirolimus Phase 2 Not yet recruiting Beijing Konruns Pharmaceutical Co., Ltd. 2026-11-16 Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. Everolimus, Sirolimus Phase 2 Recruiting Kidney Cancer Research Bureau 2026-11-16 Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE) Sirolimus Early phase 1 Not yet recruiting Biosensors Europe SA 2026-11-16 Effect of Sirolimus on Oocyte Quality in Women Undergoing IVF Sirolimus, Temsirolimus Phase 4 Recruiting Center for Human Reproduction 2026-11-13 Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm Exploratory Study Tacrolimus anhydrous Phase 2 Not yet recruiting The First Affiliated Hospital of Soochow University 2026-11-09 Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT) Sirolimus Not applicable Not yet recruiting Sir Run Run Shaw Hospital 2026-11-05 Efficacy of Fractional Co2 Laser With Topical Tacrolimus 0.1 in the Treatment of Nail Psoriasis Tacrolimus anhydrous Not applicable Not yet recruiting Cairo University 2026-11-05 Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases Everolimus — Enrolling by invitation Chiyi Chen 2026-11-03 ADVA ACE Coronary Stent System in Coronary Artery Disease Patients (ADVANCE) Everolimus Not applicable Not yet recruiting Advanced MedTech Solutions Pvt. Ltd. 2026-11-03 Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo Tacrolimus anhydrous Not applicable Enrolling by invitation Kafrelsheikh University 2026-11-02 Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study. Tacrolimus anhydrous Phase 3 Recruiting Cairo University 2026-10-29 A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer. Everolimus, Sirolimus Phase 2 Recruiting The First Affiliated Hospital with Nanjing Medical University 2026-10-28 Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy Tacrolimus anhydrous Phase 2 Not yet recruiting Ronald Paquette 2026-10-27 Microbiota Changes Related to Outcomes in Kidney Transplantation Tacrolimus anhydrous — Not yet recruiting Hospices Civils de Lyon 2026-10-26 Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. Tacrolimus anhydrous Phase 3 Not yet recruiting Cairo University 2026-10-23 Study on the Safety and Efficacy of a Time-of-Day-Based Individualized Tacrolimus Dosing Regimen in Kidney Transplant Recipients Tacrolimus anhydrous Phase 4 Not yet recruiting The First Affiliated Hospital of Guangzhou Medical University 2026-10-16 Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma Everolimus, Sirolimus Phase 1 Not yet recruiting Bożenna Dembowska Bagińska 2026-10-08 Laser Atherectomy and Sirolimus-eluting Balloon Angioplasty for CLTI Sirolimus — Active, not recruiting Attikon Hospital 2026-10-05 Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Temsirolimus Phase 1 / Phase 2 Not yet recruiting University Hospital, Strasbourg, France 2026-10-01 Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder Temsirolimus Phase 1 Recruiting OHSU Knight Cancer Institute 2026-09-28 A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers Temsirolimus Phase 1 / Phase 2 Not yet recruiting Advenchen Pharmaceuticals, LLC. 2026-09-10 A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers Temsirolimus Phase 1 / Phase 2 Not yet recruiting Advenchen Pharmaceuticals, LLC. 2026-09-10 A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting Stent for Reducing Immediate Post-Procedural Slow-Flow/No-Reflow in Acute ST-Elevation Myocardial Infarction Patients With High Thrombus Burden Everolimus, Zotarolimus — Recruiting Xijing Hospital 2026-09-08 A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies Everolimus, Temsirolimus — Not yet recruiting Novartis Pharmaceuticals 2026-08-17 Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) Temsirolimus Phase 3 Recruiting Hannover Medical School 2026-07-31 A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies Temsirolimus Phase 1 / Phase 2 Recruiting Umoja Biopharma 2026-07-30 Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy. Pimecrolimus Not applicable Not yet recruiting Milosz Pietrus 2025-11-20 The European Bifurcation Club Randomized Trial of Stepwise Provisional Stenting Versus Drug Coated Balloon Therapy for Non-left Main True Coronary Bifurcations Zotarolimus Not applicable Not yet recruiting Ceric Sàrl 2025-02-12 The Study to Evaluate the Safety and Efficacy of the Onyx Family Zotarolimus — Recruiting Pusan National University Yangsan Hospital 2024-08-29 MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels Zotarolimus Not applicable Recruiting Concept Medical Inc. 2024-02-22 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor Pimecrolimus Phase 3 Active, not recruiting Sanofi 2024-02-05 Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis. Pimecrolimus — Active, not recruiting BGP Products Operations GmbH, a Viatris company 2023-09-25 Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT Zotarolimus — Active, not recruiting Yonsei University 2022-04-22 Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial Zotarolimus Not applicable Recruiting Yonsei University 2022-04-11 Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) Zotarolimus Not applicable Active, not recruiting Elixir Medical Corporation 2020-09-24 Firehawk Rapamycin Target Eluting Coronary Stent North American Trial Zotarolimus Not applicable Active, not recruiting Shanghai MicroPort Medical (Group) Co., Ltd. 2020-09-24 10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus Pimecrolimus — Active, not recruiting Bausch Health Americas, Inc. 2007-12-06
Show all 37Diseases Most Associated With It Open Targets association score, 0 to 1; all associations
Atopic eczema 0.60
Kidney transplant 0.59
Liver transplant 0.59
Tuberous sclerosis 0.57
Graft versus host disease 0.56
Neoplasm 0.55
Kidney angiomyolipoma 0.54
Neuroendocrine neoplasm 0.53
Hamartoma 0.53 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1902 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-18. Gene name, function (UniProt P62942 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets